Methods for reducing interferences

Patent metadata

Field	Value
Publication number	US-12399176-B2
Application number	US-202117482700-A
Country	US
Kind code	B2
Filing date	Sep 23, 2021
Priority date	Dec 18, 2014
Publication date	Aug 26, 2025
Grant date	Aug 26, 2025

Abstract

A method for determining an analyte in a sample suspected to comprise the analyte, includes a) contacting with said sample at least a first and a second capture compound for the analyte; b) contacting the capture compounds contacted with the sample with a specifier; c) determining the amount of complexes comprising the specifier and a capture compound; and d) determining the analyte in a sample based on the result of step c). Additionally, a method for improving the specificity of an indirect immunoassay for determining an analyte, kits, devices, and uses related to the aforementioned methods are also disclosed.

First claim

The invention claimed is:

1. A kit for detecting an analyte in a sample, comprising
at least two non-identical capture compounds for said analyte, or
at least two non-identical detector compounds for said analyte,
wherein said at least two non-identical capture compounds or detector compounds are non-identical polypeptides differing in at least one property selected from the group consisting of amino acid sequence, glycosylation, three-dimensional folding and/or conformation, and length of polypeptide chain, and
wherein said at least two non-identical capture compounds or detector compounds compete in binding to said analyte.

2. The kit of claim 1 , wherein said at least two non-identical capture compounds or said at least two non-identical detector compounds comprise the same analyte binding domain.

3. The kit of claim 1 , wherein said kit comprises at least two non-identical capture compounds.

4. The kit of claim 3 , wherein said at least two non-identical capture compounds have amino acid sequences sharing at least 70% sequence identity.

5. The kit of claim 3 , wherein said at least two non-identical capture compounds are bound to a solid surface or are adapted to be bound to a solid surface.

6. The kit of claim 3 , wherein said kit further comprises at least one antibody forming capture complexes with said at least two capture compounds.

7. The kit of claim 6 , wherein said at least one antibody is bound to a solid surface or is adapted to be bound to a solid surface.

8. The kit of claim 3 , wherein said at least two non-identical capture compounds are direct ligands of said analyte.

9. The kit of claim 1 , wherein said kit comprises from 2 to 10 capture compounds for said analyte, from 2 to 5 capture compounds for said analyte, from 2 to 4 capture compounds for said analyte, or from 2 to 3 capture compounds for said analyte.

10. The kit of claim 3 , wherein said kit further comprises a specifier.

11. The kit of claim 10 , wherein said specifier comprises at least a portion of the analyte bound by the at least two non-identical capture compounds, bonded to an indicator.

12. The kit of claim 10 , wherein the specifier consists of the analyte covalently bonded to an indicator.

13. The kit of claim 1 , wherein said kit comprises at least two non-identical detector compounds, said detector compounds each comprising said analyte binding domain and an indicator.

14. The kit of claim 13 , wherein said at least two non-identical detector compounds have amino acid sequences sharing at least 70% sequence identity.

15. The kit of claim 13 , wherein said at least two non-identical detector compounds comprise the same indicator.

16. The kit of claim 13 , wherein said indicator has a detectable property selected from the group consisting of an optical property, an enzymatic property, and a property of emitting radioactivity.

17. The kit of claim 13 , wherein said at least two non-identical detector compounds are direct ligands of said analyte.

18. The kit of claim 1 , wherein said kit comprises from 2 to 10 detector compounds for said analyte, from 2 to 5 detector compounds for said analyte, from 2 to 4 detector compounds for said analyte, or from 2 to 3 detector compounds for said analyte.

19. The kit of claim 1 , wherein said at least two non-identical capture compounds or said at least two non-identical detection compounds do not compete in binding to an interfering compound.

20. The kit of claim 1 , wherein a first capture compound or a first detector compound comprises an amino acid sequence at least 70% identical to SEQ ID NO:1, and/or wherein a second capture compound or a second detector compound comprises an amino acid sequence at least 70% identical to SEQ ID NO:2.

Assignees

• Roche Diagnostics Operations Inc

Inventors

• Upmeier Barbara
• Zarnt Toralf
• Polz Johannes

Classifications

• G01N2800/26

  Infectious diseases, e.g. generalised sepsis · CPC title

• G01N33/6854

  Immunoglobulins · CPC title

• G01N33/54306 Primary

  Solid-phase reaction mechanisms · CPC title

• G01N33/54393 Primary

  Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding · CPC title